Quantifying the Impact of Influenza Among Persons With Type 2 Diabetes Mellitus: A New Approach to Determine Medical and Physical Activity Impact.

consumer wearable devices diabetes mellitus health outcomes influenza infection patient generated health data

Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
01 2021
Historique:
pubmed: 22 11 2019
medline: 29 10 2021
entrez: 22 11 2019
Statut: ppublish

Résumé

We describe the impact of influenza on medical outcomes and daily activities among people with and without type 2 diabetes mellitus (T2DM). Retrospective cohort analysis of a US health plan offering a digital wellness platform connecting wearable devices capable of tracking steps, sleep, and heart rate. For the 2016 to 2017 influenza season, we compared adults with T2DM to age and gender matched controls. Medical claims were used to define cohorts and identify influenza events and outcomes. Digital tracking data were aggregated at time slices of minute-, day-, week-, and year-level. A pre-post study design compared the peri-influenza period (two weeks before and four weeks after influenza diagnosis) to the six-week preceding period (baseline). A total of 54 656 T2DM and 113 016 non-DM controls were used for the study. People with T2DM had more influenza claims, vaccinations, and influenza antivirals per 100 people (1.96% vs 1.37%, 34.3% vs 24.3%, and 27.1 vs 22 respectively, Influenza increases rates of pneumonia, heart disease, and abnormal glucose levels among people with T2DM, and negatively impacts daily activities compared to controls.

Sections du résumé

BACKGROUND
We describe the impact of influenza on medical outcomes and daily activities among people with and without type 2 diabetes mellitus (T2DM).
METHODS
Retrospective cohort analysis of a US health plan offering a digital wellness platform connecting wearable devices capable of tracking steps, sleep, and heart rate. For the 2016 to 2017 influenza season, we compared adults with T2DM to age and gender matched controls. Medical claims were used to define cohorts and identify influenza events and outcomes. Digital tracking data were aggregated at time slices of minute-, day-, week-, and year-level. A pre-post study design compared the peri-influenza period (two weeks before and four weeks after influenza diagnosis) to the six-week preceding period (baseline).
RESULTS
A total of 54 656 T2DM and 113 016 non-DM controls were used for the study. People with T2DM had more influenza claims, vaccinations, and influenza antivirals per 100 people (1.96% vs 1.37%, 34.3% vs 24.3%, and 27.1 vs 22 respectively,
CONCLUSION
Influenza increases rates of pneumonia, heart disease, and abnormal glucose levels among people with T2DM, and negatively impacts daily activities compared to controls.

Identifiants

pubmed: 31747789
doi: 10.1177/1932296819883340
pmc: PMC7780362
doi:

Substances chimiques

Hypoglycemic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

44-52

Références

Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
pubmed: 23210147
JAMA. 1999 Mar 10;281(10):901-7
pubmed: 10078486
Clin Infect Dis. 2014 Mar;58(6):775-84
pubmed: 24352349
Am J Physiol Regul Integr Comp Physiol. 2017 Mar 1;312(3):R358-R367
pubmed: 28052867
J Med Internet Res. 2012 Oct 04;14(5):e125
pubmed: 23037553
Diabetes Res Clin Pract. 1991 Apr;12(1):61-8
pubmed: 1906798
Vaccine. 2019 Jul 26;37(32):4594-4600
pubmed: 29699784
Sci Rep. 2017 Jun 12;7(1):3216
pubmed: 28607474
Lancet. 2003 Nov 22;362(9397):1733-45
pubmed: 14643124
Clin Infect Dis. 2014 Jan;58(2):214-24
pubmed: 24186906
Vaccine. 2017 Sep 12;35(38):5095-5101
pubmed: 28807608
Heart. 2015 Nov;101(21):1738-47
pubmed: 26310262
Diabetes Care. 2010 Jul;33(7):1491-3
pubmed: 20587722
N Engl J Med. 2018 Jan 25;378(4):345-353
pubmed: 29365305
Vaccine. 2018 Jun 22;36(27):3960-3966
pubmed: 29801998
PLoS One. 2011 Apr 27;6(4):e18687
pubmed: 21556151
Sensors (Basel). 2016 May 05;16(5):
pubmed: 27164110
J Med Internet Res. 2016 Sep 07;18(9):e239
pubmed: 27604226
Clin Infect Dis. 2018 Jun 18;67(1):8-17
pubmed: 29324996
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
J Diabetes Sci Technol. 2018 Jan;12(1):199-201
pubmed: 28539086
Ther Innov Regul Sci. 2017 Jul;51(4):468-470
pubmed: 30227056
MMWR Recomm Rep. 2013 Sep 20;62(RR-07):1-43
pubmed: 24048214
Heart. 2016 Dec 15;102(24):1953-1956
pubmed: 27686519
Diabetologia. 2014 Apr;57(4):690-8
pubmed: 24496923

Auteurs

Sandrine I Samson (SI)

Sanofi Pasteur, Global Medical Affairs, Swiftwater, PA, USA.

Kevin Konty (K)

Evidation Health, Santa Barbara, CA, USA.

Wei-Nchih Lee (WN)

Evidation Health, Santa Barbara, CA, USA.

Tom Quisel (T)

Evidation Health, Santa Barbara, CA, USA.

Luca Foschini (L)

Evidation Health, Santa Barbara, CA, USA.

David Kerr (D)

Sansum Diabetes Research Institute, Santa Barbara, CA, USA.

Jan Liska (J)

Sanofi, Patient Solutions, Paris, France.

Henry Mills (H)

Sanofi Pasteur, Global Medical Affairs, Lyon, France.

Rosalind Hollingsworth (R)

Sanofi Pasteur, Global Medical Affairs, Swiftwater, PA, USA.

Michael Greenberg (M)

Sanofi Pasteur, Global Medical Affairs, Lyon, France.

Anne C Beal (AC)

Sanofi, Patient Solutions, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH